Wednesday, July 8, 2026

biotech · Breast Cancer · Advanced Breast Cancer · PBYI

PUMA BIOTECHNOLOGY

PUMA BIOTECHNOLOGY clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

10880 Wilshire Blvd, Los Angeles, CA 90024, US HQ
2010 Founded
257 Employees
Public company Type
PBYI · NYSE Ticker
Company details
Status
Public
HQ
10880 Wilshire Blvd, Los Angeles, CA 90024, US
Founded
2010
Employees
257
Programs
40
Drugs
23
Patents
1
Intelligence · Clinical Programs

PUMA BIOTECHNOLOGY projects

1 ClinicalTrials.gov programs sponsored by PUMA BIOTECHNOLOGY.

PUMA BIOTECHNOLOGY has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2+ Metastatic Breast Cancer (MBC)

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does PUMA BIOTECHNOLOGY have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.